Lung cancer has the highest incidence rate among malignant tumors in China, and its mortality rate is also very high. The treatment and full-course management of lung cancer have become the focus of attention. To further promote the development of the discipline of lung cancer diagnosis and treatment, better advance the precise diagnosis, standardized treatment of lung cancer and improve the quality of life of lung cancer patients, the Chengdu High-tech Medical Association held the "Immune 2.0 Era - Special Seminar on Lung Cancer" on September 29, 2025. All are mainly composed of medical and health professionals from multiple disciplines such as oncology, respiratory medicine, thoracic surgery, radiotherapy, pathology and radiology. They focus on the themes of standardized diagnosis and treatment of lung cancer, adverse reaction management and the latest progress in lung cancer treatment. Through online communication and learning, they aim to enhance the diagnosis and treatment level of multiple disciplines in the field of lung cancer treatment. This series of conferences aims to build a high-end academic exchange platform, promote the development of related health services, facilitate academic exchanges, disciplinary integration, and the transformation of academic research into industry.